Prognostic value of sequential 18F-FDG + Na18F PET/CT (NaF+FDG PET) in metastatic genitourinary (GU) cancer patients (pts) treated with cabozantinib/nivolumab +/- ipilimumab (CaboNivoIpi).

Nicholas Peter Verdini,Ilhan Lim,Esther Mena,Liza Lindenberg,Amir Mortazavi,Sumanta K. Pal,Primo N. Lara,Katherine Graap,Marissa Mallek,Corrine Keen,Ryan Thompson,Christian Mayfield,Corinne Turrell,Jacqueline Cadena,Biren Saraiya,Ray L Lilly,Michael V. Knopp,Chadwick L. Wright,Seth M. Steinberg,Andrea B. Apolo

Prognostic value of sequential 18F-FDG + Na18F PET/CT (NaF+FDG PET) in metastatic genitourinary (GU) cancer patients (pts) treated with cabozantinib/nivolumab +/- ipilimumab (CaboNivoIpi).

2019

4544Background: NaF+FDG PET imaging are used to assess soft tissue and bone metastases. The prognostic value of NaF+FDG PET in GU cancer pts was assessed as a secondary endpoint within a phase I tr...

Keywords:

Cancer
Ipilimumab
Pathology
Nivolumab
PET-CT
Oncology
Internal medicine
Genitourinary system
Cabozantinib
Medicine
Soft tissue
Radiology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations